Compassionate use of bevacizumab (Avastin®) in children and young adults with refractory or recurrent solid tumors

Annals of Oncology

Volumn 19, Issue 4, 2008, Pages 807-813

  Benesch, Martin ^a   Windelberg, M ^b   Sauseng, W ^a   Witt, V ^c   Fleischhack, G ^b   Lackner, H ^a   Gadner, H ^c   Bode, U ^b   Urban, C ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF BONN   (Germany)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Angiogenesis; Bevacizumab; Children; Refractory solid tumors

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; INTERLEUKIN 2; IRINOTECAN; METHOTREXATE; PEGINTERFERON ALPHA; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN; TROFOSFAMIDE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; ERYTHEMA; FEMALE; GLIOBLASTOMA; HEMATURIA; HUMAN; HYPERTENSION; INFANT; INTRACRANIAL TUMOR; KIDNEY CARCINOMA; MALE; MUSCLE HYPERTONIA; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEINURIA; RHABDOMYOSARCOMA; SOLID TUMOR; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; WOUND HEALING IMPAIRMENT;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ASTROCYTOMA; BRAIN NEOPLASMS; CARCINOMA; CHILD; DRUG ADMINISTRATION SCHEDULE; EMPATHY; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEUROBLASTOMA; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; SARCOMA; TOMOGRAPHY, X-RAY COMPUTED; WILMS TUMOR;

EID: 41549107098     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm510     Document Type: Article

References (32)

1. Magnani C, Pastore G, Coebergh JW et al. Trends in survival after childhood cancer in Europe. 1978-1997: Report from the Automated Childhood Cancer Information System project (ACCIS). Eur J Cancer 2006; 42: 1981-2005.
2. Ceschel S, Casotto V, Valsecchi MG et al. Survival after-relapse in children with solid tumors: A follow-up study from the Italian Off-Therapy Registry. Pediatr Blood Cancer 2006; 47: 560-566.
3. Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 2005; 23: 4354-4362.
4. Kempf-Bielack B, Bielack, SS, Jürgens H et al. Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group. J Clin Oncol 2005; 23: 559-568.
5. Pappo AS, Anderson JR, Crist WM et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 1999; 17: 3487-3493.
6. Wagner S, Benesch M, Berthold F et al. Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas. Br J Cancer 2006; 95: 991-997.
7. Goldberg RM. Therapy for metastatic colorectal cancer. Oncologist 2006; 11: 981-987.
8. Stadler WM. Targeted therapy for the treatment of advanced renal cell carcinoma. Cancer 2005; 104: 2323-2333.
9. Druker BJ. Molecularly targeted therapy: Have the floodgates opened? Oncologist 2004; 9: 357-360.
10. Wong C, Wellman TL, Lounsbury KM. VEGF and HIF-1α expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol 2003; 91: 513-517.
11. Han H, Silverman JF, Santucci TS et al. Vascular-endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001; 8: 72-79.
12. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
13. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
14. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335--2342.
15. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
16. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
17. Crane CH, Ellis LM, Abbruzzese JL et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006; 24: 1145-1151.
18. Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncoll 2006; 24: 1898-1903.
19. Zon R, Miller K, Wang M et al. A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern Cooperative Oncology Group trial E2100. Eur J Cancer 2006; 4 (Suppl): 47.
20. Hatva E, Kaipainen A, Mentula P et al. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol 1995; 146: 368-378.
21. Hatva E, Böhling T, Jääskeläinen J et al. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol 1996; 148: 763-775.
22. Meister B, Grüsebach F, Bautz F et al. Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma. Eur J Cancer 1999; 35: 445-449.
23. Gee MF, Tsuchida R, Eichler-Jonsson C et al. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 2005; 24: 8025-8037.
24. Ghanem MA, van Steenbrugge GJ, Sudaryo MK et al. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol 2003; 56: 107-113.
25. Dalal S, Berry AM, Cullinane CJ et al. Vascular endothelial growth factor: A therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 2005; 11: 2364-2378.
26. Segerström L, Fuchs D, Bäckman U et al. The anti-VEGF arrdbody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res 2006; 60: 576-581.
27. Joshi DD, Banerjee T. Vascular endothelial growth factor (VEGF) receptor antibody bevacizumab (Avastin) induce regression of renal cell carcinoma in an adolescent resulting in residual tumorectomy. Pediatr Blood Cancer 2007: May 7 [Epub ahead of print].
28. Glade Bender JL, Adamson PC, Baruchel S et al. A phase I study of bevacizumab in children with refractory solid tumors: A Children's Oncology Group study. J Clin Oncol 2006; 24 (Suppl 18): 9017.
29. Kirkpatrick J, Desjardins A, Vredenburgh JJ et al. Combination of bevacizumab, a monocloncal antibody to vascular endotheliAl growth factor (VEGF), and temozolomide: Study of cases. J Clin Oncol 2006; 24 (Suppl 18): 11522.
30. Miyagami M, Katayama Y, Nakamura S. Clinicopathological study of vascular endothelial growth factor (VEGF), p53, and proliferative potential in familial von Hippel-Lindau disease and sporadic hemangioblastomas. Brain Tumor Pathol 2000; 17: 111-120.
31. Hearn J, Sullivan R. The impact of the 'Clinical Trials' directive on the cost and conduct of non-commercial cancer trials in the UK. Eur J Cancer 2007; 43: 8-13.
32. Hoey R. The EU Clinical Trials Directive: 3 years on. Lancet 2007; 369: 1777-1778.